ALPHA-2, NCT04416984: Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2) |
|
|
| Recruiting | 1/2 | 160 | Europe, Canada, US, RoW | ALLO-501A, ALLO-647, Fludarabine, Cyclophosphamide | Allogene Therapeutics | Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma | 01/25 | 05/29 | | |
